Dapagliflozin in HFrEF Low eGFR

**Yes, dapagliflozin is recommended for HFrEF patients with an eGFR below 30 mL/min/1.73 m², provided it is not initiated below 25 mL/min/1.73 m², and continuation is supported even below 20 mL/min/1.73 m² based on recent label updates and clinical trial data.** --- ## Clinical Evidence & Efficacy The cardiovascular benefits of SGLT2 inhibitors (SGLT2i) in heart failure with reduced ejection fraction (HFrEF) are preserved across a wide range of renal function, including advanced chronic kidney disease (CKD). - **Pivotal trial inclusion criteria**: The landmark HFrEF trials for dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) enrolled patients with eGFR as low as 20–30 mL/min/1.73 m². Importantly, participants whose eGFR fell below 20 mL/min/1.73 m² during the trials **continued treatment** and derived considerable benefit [3]. - **Renal and cardiovascular protection**: The committee for the NICE guideline [NG28] noted that the cardiovascular and renal protective effects of SGLT2i are retained at eGFR values below 30 mL/min/1.73 m², even though the glycemic benefits may diminish or be absent [1]. - **Expected eGFR dip**: A transient drop in eGFR is expected upon SGLT2i initiation due to increased afferent glomerular arteriolar tone. Clinicians should **not** adjust or discontinue the medication solely based on this expected change [3]. ## Dosing & Administration The initiation threshold for dapagliflozin has been updated in recent regulatory labels and guidelines. | Source | Initiation Threshold | Continuation Below Threshold | |--------|---------------------|------------------------------| | **2024 ACC Expert Consensus** | Lower limit of **25 mL/min/1.73 m²** for dapagliflozin [3] | Supported; trial participants continued below 20 mL/min/1.73 m² with benefit [3] | | **2022 CCS Guidelines** | Initiation not recommended for eGFR < **25 mL/min/1.73 m²** [5] | N/A | | **UK Kidney Association** | Not recommended to initiate if eGFR < **15 mL/min/1.73 m²** [6] | N/A | | **ADA/KDIGO Consensus** | Approved for use at 10 mg once daily with eGFR **25 to <45 mL/min/1.73 m²** [4] | Higher dose not effective for glucose lowering but CV benefit preserved [4] | **Standard dosing for HFrEF**: Dapagliflozin **10 mg orally once daily**. ## Safety Profile ### Contraindications and Precautions - **Absolute contraindications**: End-stage kidney disease (KF) and patients on dialysis [2]. - **Initiation caution**: Do not initiate dapagliflozin when eGFR is persistently <25 mL/min/1.73 m² [3][5]. - **Monitoring**: Closer monitoring of renal function and electrolytes is advised in patients with eGFR <30 mL/min/1.73 m² [3]. ### Adverse Effects - **Common**: Genital mycotic infections, volume depletion (especially with concurrent diuretic use), and the expected initial eGFR dip. - **Serious but rare**: Euglycemic diabetic ketoacidosis (eDKA), Fournier gangrene (necrotizing fasciitis of the perineum). ## Guideline Recommendations The following clinical workflow illustrates the initiation and management of SGLT2i in the context of HFrEF and CKD: **The following flowchart outlines the clinical management pathway for SGLT2 inhibitor use:**  *Figure: A clinical workflow for the initiation and management of SGLT2 inhibitors (SGLT2i), detailing indications, renal-specific contraindications, and dose adjustments for concomitant therapies.* The quadruple therapy foundation for HFrEF (ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2i) is recommended regardless of baseline eGFR, with the renal-specific caveats noted above. **The following diagram illustrates the GDMT pathway for Stage C HFrEF:**  *Figure: This flowchart outlines the guideline-directed medical therapy (GDMT) for Stage C Heart Failure with Reduced Ejection Fraction (HFrEF), prioritizing a quadruple therapy foundation followed by targeted add-on treatments.* ## Critical Gaps - The available evidence does not provide specific guidance on the optimal monitoring frequency (e.g., serum creatinine, potassium) for patients with eGFR <30 mL/min/1.73 m² on dapagliflozin. - Long-term safety data (beyond 2–3 years) for SGLT2i in patients with eGFR persistently <25 mL/min/1.73 m² are limited. ## Conclusion Dapagliflozin is a recommended component of the "foundational four" for HFrEF even when eGFR is below 30 mL/min/1.73 m², with initiation supported down to 25 mL/min/1.73 m² and continuation of therapy below that threshold supported by clinical trial data and recent label updates. --- *This response is based on retrieved clinical guidelines and expert consensus documents. Always verify against the latest official prescribing information and apply individual patient-specific clinical judgment.*